Linkage of Medicaid Enrollment Information to Surveillance, Epidemiology and End Results Data

Sponsor
National Cancer Institute (NCI) (NIH)
Overall Status
Completed
CT.gov ID
NCT02875327
Collaborator
(none)
3,217,145
1
45.5
70752.8

Study Details

Study Description

Brief Summary

Background:

The SEER database collects data about people with cancer. SEER stands for Surveillance, Epidemiology, and End Results. Medicaid is a kind of health insurance. It is for people who have low income or serious medical needs. Many studies have shown that Medicaid recipients with cancer are more likely to be diagnosed later in the disease than people with other insurance. They are also less likely to get treatment. Researchers want to compare Medicaid data and SEER data. They want to make this available to other scientists.

Objectives:

To link people in the SEER database to Medicaid data for the years around their cancer diagnosis. To create a file that contains SEER case numbers linked to Medicaid numbers.

Eligibility:

No people are enrolled in this study.

Design:

The SEER finder file will be securely uploaded to the CMS Data Center.

The finder file will be matched against the Medicaid Personal Summary file at the CMS Data Center.

If participants appear in both the SEER file and Medicaid file, their data will be extracted.

The dates of Medicaid data will be compared with the SEER date of diagnosis. Researchers will see if the Medicaid dates fall in certain periods. These are 12 months before, the month of, and 11 months after diagnosis.

If participants are eligible for Medicaid for these periods, a flag will be created in the file. It will note the participants is eligible and why.

The SEER finder file will be destroyed.

The only data saved will be:

Each participant's unique random SEER case number linked to their Medicaid number

Monthly flags about Medicaid eligibility

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Numerous studies have demonstrated that Medicaid recipients with cancer are more likely to be diagnosed at an advance stage and less likely to receive recommended treatment than are patients with other types of health insurance. The objective of this project is to link persons included in the Surveillance, Epidemiology and End Results (SEER) data to Medicaid enrollment information during the year before and after their cancer diagnosis. NCI is also seeking permission to create and maintain a file that crosswalks each patient's SEER case number to their Medicaid enrollment number. Information about Medicaid enrollment would be available by special request to all researchers who want to use SEER data to assess the impact of Medicaid enrollment on stage and treatment.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    3217145 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Linkage of Medicaid Enrollment Lnformation to Surveillance, Epidemiology and End Results Data
    Actual Study Start Date :
    Aug 5, 2016
    Actual Primary Completion Date :
    May 20, 2020
    Actual Study Completion Date :
    May 20, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Link persons included in the Surveillance, Epidemiology and End Results (SEER) data to Medicaid enrollment information [7 years]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Year to 120 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    • INCLUSION:

    • Cancer Diagnosis

    • Medicaid Member

    • Registered within the SEER Program

    EXCLUSION:

    -None

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Cancer Institute (NCI) Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Lindsey R Enewold, Ph.D., National Cancer Institute (NCI)

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    National Cancer Institute (NCI)
    ClinicalTrials.gov Identifier:
    NCT02875327
    Other Study ID Numbers:
    • 999916163
    • 16-C-N163
    First Posted:
    Aug 23, 2016
    Last Update Posted:
    May 21, 2020
    Last Verified:
    May 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Keywords provided by National Cancer Institute (NCI)

    Study Results

    No Results Posted as of May 21, 2020